Target intelligence / Profile preview

Heat shock protein 105 (HSP105)

Target
HSP105
Molecular classification
Molecular chaperone, Heat shock protein (Hsp70 superfamily), Nucleotide exchange factor
01

Overview

Heat shock protein 105 (HSP105, also known as Hsp110, encoded by HSPH1) is a large molecular chaperone in the Hsp70 superfamily, most highly abundant in brain and multiple other tissues[1][3]. It functions as both a nucleotide exchange factor for chaperones like Hsc70 and a holdase to prevent aggregation of denatured or misfolded proteins under stress conditions, helping maintain protein homeostasis and promote cell survival[1][3]. HSP105 can be highly induced by multiple proteotoxic stresses, is cytoprotective, and has a pivotal role in apoptosis regulation and immune modulation by presenting protein antigens for immune responses[1][2]. Overexpression of HSP105 is linked to cancer cell survival, chemoresistance, and has also been observed in neurodegeneration and inflammatory conditions[1][2]. Pharmacological modulation or targeted therapies (e.g., siRNA) may have therapeutic potential in oncology and neuroprotection, but systemic manipulation poses safety and specificity challenges[1][2].

Other names
HSP105Hsp110Heat shock 105kD proteinHSPH1Hsp105αHsp105β
02

Mechanism of action

Small interfering RNA (siRNA): suppression of HSP105 expression leads to cancer cell apoptosis through caspase-mediated mechanisms (independent of p53). Induction by small molecules (e.g., celastrol): upregulation of HSP105 confers cytoprotection in injury models.

03

Biological functions

Protein homeostasis (proteostasis)Prevention of protein aggregationCytoprotection under stress (heat shock, oxidative stress, hypoxia, etc.)Regulation of apoptosisImmune modulation (chaperoning antigens for immune presentation)Cellular stress response
04

Disease associations

CancerNeurodegenerative diseaseInflammatory disease
05

Safety considerations

Potential tumor-protective function: overexpression of HSP105 in cancer cells contributes to resistance to apoptosis, suggesting possible adverse effect if globally upregulated in cancersFunctions in essential cellular stress responses, so broad inhibition may lead to toxicity in normal tissuesImmunogenicity risk when used as part of vaccine strategies or therapies
06

Interacting drugs

celastrol (induces Hsp110 expression in models of traumatic brain injury)

2 more in the full profile.

07

Biomarkers

HSP105 overexpression as a potential biomarker in various cancers for diagnostic and therapeutic targetingPossible marker for cellular stress response and tissue injury

Beyond the preview

Go deeper on Heat shock protein 105 (HSP105).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heat shock protein 105 (HSP105).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call